Can a simple blood test predict cancer treatment success?

NCT ID NCT04892849

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This observational study is collecting blood samples and medical images from 200 people with several types of solid tumors (like lung, head and neck, and esophageal cancers) who are receiving immunotherapy and radiation as part of their standard care. Researchers want to see if changes in immune cells in the blood or patterns in scans can predict how well the treatment works or if side effects occur. The goal is to find reliable markers that could guide future treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could identify blood or imaging markers that help predict which patients benefit most from combining immunotherapy with radiation.

What could go wrong

This is an observational study, not testing a new treatment. It may not find reliable biomarkers, and results may not apply to all patients or cancer types.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms head and neck squamous cell carcinoma non-small cell lung carcinoma renal cell carcinoma skin squamous cell carcinoma small cell lung carcinoma Squamous Cell Carcinoma of Head and Neck transitional cell carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Radiation Oncology, Universitätsklinikum Erlangen

    RECRUITING

    Erlangen, Bavaria, 91054, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact